Cancer cells as a new source of induced pluripotent stem cells.
Azam ShamsianRoxana SahebnasaghAmir NorouzySafin Hassan HusseinMohammad Hossein GhahremaniZahra AziziPublished in: Stem cell research & therapy (2022)
Over the last 2 decades, induced pluripotent stem cells (iPSCs) have had various potential applications in various medical research areas, from personalized medicine to disease treatment. Different cellular resources are accessible for iPSC generation, such as keratinocytes, skin fibroblasts, and blood or urine cells. However, all these sources are somatic cells, and we must make several changes in a somatic cell's transcriptome and chromatin state to become a pluripotent cell. It has recently been revealed that cancer cells can be a new source of iPSCs production. Cancer cells show similarities with iPSCs in self-renewal capacity, reprogramming potency, and signaling pathways. Although genetic abnormalities and potential tumor formation in cancer cells pose a severe risk, reprogrammed cancer-induced pluripotent stem cells (cancer-iPSCs) indicate that pluripotency can transiently overcome the cancer phenotype. This review discusses whether cancer cells can be a preferable source to generate iPSCs.
Keyphrases
- induced pluripotent stem cells
- papillary thyroid
- single cell
- induced apoptosis
- genome wide
- squamous cell
- healthcare
- signaling pathway
- cell cycle arrest
- copy number
- gene expression
- lymph node metastasis
- cell therapy
- rna seq
- stem cells
- transcription factor
- dna damage
- early onset
- endoplasmic reticulum stress
- dna methylation
- risk assessment
- drinking water
- bone marrow
- cell death
- replacement therapy
- smoking cessation